Eli Lilly Acquires AtaiBeckley for $2.8 Billion in Bid for Neuroscience Treatments

Eli Lilly confirmed Thursday its acquisition of AtaiBeckley, the biopharmaceutical company, for an upfront payment of $2.8 billion, with potential to reach $3.8 billion. The news caused AtaiBeckley’s stock to jump over 30% in pre-market trading. The transaction grants Eli Lilly access to AtaiBeckley’s experimental therapies, including a drug being studied for treatment-resistant depression. According to sources, the deal gives Lilly technology that aims to promote new neural connections, differing from conventional antidepressant methods. Dan Skovronsky, chief scientific officer at Eli Lilly, noted the goal is to change the physical connections within the brain. The deal marks a notable development in the area, occurring as the administration previously emphasized the development of psychedelic-based treatments for mental health issues. While the acquisition represents a significant financial move for Eli Lilly, some investors expressed a preference for AtaiBeckley to remain independent to shepherd its pipeline drugs into late-stage trials. Lilly’s stated interest is developing advanced pharmaceuticals for serious medical needs.

Sources